Sustained Release Intraocular Implants and Methods for Treating Ocular Neuropathies

• US 20110091520A1
• Filed: 11/29/2010
• Published: 04/21/2011
• Est. Priority Date: 04/30/2004
• Status: Active Grant

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Huang, Glenn T., Nivaggioli, Thierry
• Granted Patent: US 8,715,709 B2
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta adrenergic receptor antagonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular neuropathies, for example, various forms of glaucoma.

Claims

1-18. -18. (canceled)

19. A method of reducing intraocular pressure in an eye of a patient, comprising the step of placing a biodegradable drug delivery implant comprising:

a beta adrenergic race for antagonist associated with a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the beta adrenergic receptor antagonist from the implant for a time effective to reduce intraocular pressure in an eye in which the implant is placed, the time being at least about one week after the implant is in the eye, wherein said beta adrenergic receptor antagonist is timolol and salts thereof, and is in an amount of from 10 to 26%, by weight, of said implant, in an eye of the patient to provide a therapeutically effective amount of the beta adrenergic receptor antagonist to the patient for at least about one week.

20. (canceled)

21. A method of reducing intraocular pressure in an eye of a patient, comprising the step of placing a biodegradable drug delivery implant comprising:

a beta adrenergic receptor antagonist associated with a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the beta adrenergic receptor antagonist from the implant for a time effective to reduce intraocular pressure in an eye in which the implant is placed, the time being at least about one week after the implant is placed in the eye, wherein said beta adrenergic receptor antagonist is timolol and is provided in an amount of from 10 to 26%, by weight of said implant and wherein the beta adrenergic receptor antagonist is dispersed within the biodegradable polymer matrix in an eye of the patient to provide a therapeutically effective amount of the beta adrenergic receptor antagonist to the patient for at least about one week.

22. A method of reducing intraocular pressure in an eye of a patient, comprising the step of placing a biodegradable drug delivery implant comprising:

a beta adrenergic receptor antagonist associated with a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the beta adrenergic receptor antagonist from the implant for a time effective to reduce intraocular pressure in an eye in which the implant is placed the time being at least about one week after the implant is placed in the eye, wherein said beta adrenergic receptor antagonist is timolol maleate and is provided in an amount of from 10 to 26%, by weight, of said implant and wherein the beta adrenergic receptor antagonist is dispersed within the biodegradable polymer matrix in an eye of the patient to provide a therapeutically effective amount of the beta adrenergic receptor antagonist to the patient for at least about one week.

23-30. -30. (canceled)